Studies on molecular biology have considerably enhanced our understanding of congenital coagulation disorders but have failed so far to supply tools for an adequate classification of defects. In fact, mutations in the same domain may give rise to different phenotypes. Conversely, mutations in different domains, controlled by different exons, may cause similar patterns. The 37 kindreds with congenital factor X (FX) deficiency, known to have a defect in the catalytic domain, have been evaluated in an attempt to investigate the genotype—phenotype relation. Discrepant results were obtained because about half kindreds showed a type I pattern, namely a concomitant decrease in FX activity and antigen. The other half showed a type II pattern, namely a decrease in FX activity with a normal or near normal FX antigen. In a few instances, the allocation of the kindred either to type I or to type II defect could not be reached, due to the lack of information about the antigen.
The comparison of the kindreds in which the same mutation has been discovered by different investigations is not always possible also for lack of information.
The study analyzes the need to have a multipronged approach to the study of congenital FX deficiency. The indication of a mutation in a given domain does not provide clear information about the phenotype.
Uprichard J. , Perry DJFactor X deficiency. Blood Rev.2002;16(2):91-110.
2.
Cooper DN, Millar DS, Wacey A., Pemberton S., Tuddenham EGInherited factor X deficiency: molecular genetics and pathophysiology. Thromb Haemost. 1997;78(1):161-172.
3.
Millar DS, Elliston L., Deex P., et al. Molecular analysis of the genotype-phenotype relationship in factor X deficiency. Hum Genet. 2000;106(2):249-257.
4.
Girolami A., Scarparo P., Scandellari R., Allemand E.Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation. Am J Hematol. 2008;83(8):668-671.
5.
Girolami A., Scapin M., Scarparo P., Vettore S.Different genotypes are responsible for the normal Russell viper venom assays seen in some cases of congenital factor X deficiency. Am J Hematol. 2008;83(11):884-885.
6.
Bernardi F., Castaman G., Redaelli R., et al. Topologically equivalent mutations causing dysfunctional coagulation factors VII (294Ala→Val) and X (334Ser→Pro). Hum Mol Genet. 1994; 3(7):1175-1177.
7.
Bereczky Z., Szabo T., Haramura G., Komaromi I., Muszbek L.Two novel missense mutations (Thr233Met and Trp308Leu) in the factor X gene and their functional consequences in a patient with severe factor X deficiency . J. Thromb. Haem.2007; 5(suppl.2):O-M-024. (Abstract).
8.
Bezeaud A., Miyata T., Helley D., et al. Functional consequences of the Ser 334 Pro mutation in a human factor X variant (factor X Marseille). EurJ. Biochem. 1995; 234(10):140-147.
9.
Deam S., Srinivasan N., Westby J., Horn EH, Dolan G.FX Nottingham and FX Taunton. Two novel mutations in factor X resulting in loss of functional activity and an interpretation using molecular modelling . Thromb Haemost. 2001;85(2):265-269.
10.
Deam S., Uprichard J., Eaton JT, Perkins SJ, Dolan G.Factor X.Leichester: lle 411Phe associated with a low antigen level and a disproportionately low functional activity of factor X. J Thromb Haemost. 2003;1(3): 603-605.
11.
Deam S., Uprichard J., Eaton JT, et al. Two new factor X mutations (Pro382Leu and Phe356Cys) associated with low activity and low antigen levels. Thromb Haemost. 2004;92(5):1161-1163.
12.
Girolami A. , Vianello F., Cabrio L., Lombardi AMA new mutation (Arg251 Trp) in the Ca2+ binding site of factor X protease domain appears to be responsible for the defect in the extrinsic pathway activation of factor X Padua. Clin. Appl. Thromb. Haemost. 2004;10(1):5-8.
13.
Girolami A. , Molaro G., Lazzarin M., Scarpa R., Brunetti A.A ‘‘new’’ hemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli): A study of a large kindred. Br J Haematol. 1970 ;19(8):179-192.
14.
Girolami A. , Vicarioto M., Ruzza G., Cappellato G., Vergolani A.Factor X.Padua: A ‘‘new’’ congenital factor X abnormality with a defect only in the extrinsic system. Acta Haematol. 1985; 73(1):31-36.
15.
De Stefano V., Leone G., Ferrelli R., Hassan HJ, Macioce G., Bizzi B.Factor X.Roma: a congenital factor X variant defective at different degrees in the intrinsic and the extrinsic activation. Br J Haematol. 1988; 69(3):387-391.
16.
Herrmann FH , Navarette M., Salazar-Sanchez L., Carillo JM, Auerswald G., Wulff K.Homozygous factor X gene mutations Gly380Arg and Tyr163delAT are associated with perinatal intracranial hemorrhage. J Pediatr. 2005;146(1):128-130.
17.
Herrmann FH , Auerswald G., Ruiz-Saez A., et al. For The Greifswald Factor X Deficiency Study Group.Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia. 2006;12(5):479-489.
18.
Hougie C., Barrow EM, Graham JBStuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called stable factor (SPCA, proconvertin, factor VII) deficiency. J Clin Invest. 1957 ;36(3):485-496.
19.
Isshiki I., Favier R., Moriki T., et al. Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: In vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X. Blood Coagul Fibrinolysis. 2005; 16(1):9-16.
20.
James HL, Girolami A., Fair DSMolecular defect in coagulation factor XFriuli results from a substitution of serine for proline at position 343. Blood. 1991;77(2): 317-323.
21.
Jayandharan G., Viswabandya A., Baidya S., et al. Six novel mutations including triple heterozygosity for Phe31Ser, 514delT and 516T->G factor X gene mutations are responsible for congenital factor X deficiency in patients of Nepali and Indian origin. J Thromb Haemost. 2005; 3(7):1482-1487.
22.
Messier TL, Wong CY, Bovill EG, Long GL, Church WRFactor X.Stockton: a mild bleeding diathesis associated with an active site mutation in factor X. Blood Coagul Fibrinolysis. 1996 ;7(1):5-14.
23.
Miyata T., Kojima T., Suzuki K., et al. Factor X Nagoya 1 and Nagoya 2: a CRM- factor X deficiency and a dysfunctional CRM+ factor X deficiency characterized by substitution of Arg306 by Cys and of Gly366 by Ser, respectively. Thromb Haemost . 1998;79(3):486-490.
24.
Moroshita E., Vade A., Asakura H.Molecular genetic analysis of factor X deficiency (FX Ohmura): identification of a novel gene alteration in a Japanese family. J Thromb Haemost. 2001; (suppl):CD3372. (Abstract).
25.
Odom MW, Leone G., De Stefano V., et al. Five novel point mutations: two causing haemophilia B and three causing factor X deficiency. Mol Cell Probes. 1994; 8(1):63-65.
26.
Peyvandi F. , Menegatti M., Santagostino E., et al. Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency. Br J Haematol. 2002;117(3):685-692.
27.
Pinotti M., Camire RM, Baroni M., Rajab A., Marchetti G., Bernardi F. Impaired prothrombinase activity of Factor X Gly381Asp results in severe familial CRM+FX deficiency. Thromb Haemost. 2003;89(2):243-248.
28.
Pinotti M., Monti M., Baroni M., Marchetti G., Bernardi F.Molecular characterization of factor X deficiency associated with borderline plasma factor X level. Haematologica. 2004 ;89(4):501-502.
29.
Shen MCA novel mutation with Ins C (882-883) of the Factor X gene in a Taiwanese Chinese factor X-deficient family. Thromb Haemost. 2004;91(1):208-209.
30.
Simioni P., Vianello F., Kalafatis M., et al. A dysfunctional factor X (factor X San Giovanni Rotondo) present at homozygous and double heterozygous level: Identification of a novel microdeletion (delC556) and missense mutation (Lys(408)->Asn) in the factor X gene . A study of an Italian family. Thromb Res. 2001; 101(4):219-230.
Todd T., Perry DJ, Hayman E., Lawrence K., Gattens M., Baglin T.Severe factor X deficiency due to a homozygous mutation (Cys364Arg) that disrupts a disulphide bond in the catalytic domain. Haemophilia. 2006; 12(6):621-624.
33.
Vianello F. , Lombardi AM, Boldrin C., Luni S., Girolami A.A new factor X defect (factor X Padua 3): A compound heterozygous between true deficiency (Gly(380)->Arg) and an abnormality (Ser(334)->Pro). Thromb Res.2001;104(4):257-264.
34.
Vianello F. , Lombardi AM, Bello FD, Palù G., Zanon E., Girolami A.A novel type I factor X variant (factor X Cys350Phe) due to loss of a disulfide bond in the catalytic domain. Blood Coagul Fibrinolysis. 2003;14(4): 401-405.
35.
Greenberg BL, Davie EWBlood coagulation factors: their complementary DNAs, genes and expression . In: Geman RW, Morden V, Clowes A, Goldhaber S, eds. Hemostasis and Thrombosis . 5th ed. Philadelphia, PA: Lippincott, Williams, Wilkins; 2006:21.
36.
Girolami A. , Scandellari R., Scapin M., Vettore S.Congenital Bleeding disorders of the vitamin K-dependent clotting factors. Vitam Horm. 2008;78(1):281-374.
37.
Girolami A. , Allemand E., Scandellari R., Lombardi AM, Girolami B.The clinical and laboratory significance of cases of congenital FX deficiency due to defects in the Gla-domain. Hematology.2009;14(3):177-181.
